SCHEMBL4151237

SCHEMBL4151237

Cc1ccc(Cc2c(N3CCC(Cc4ccccc4)CC3)[nH]c(=O)n(C)c2=O)cc1

nearest known ligand 0.89

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 13/20 0.89
ALDH1A1 P00352 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
HTT P42858 1/20 0.51
MAPK1 P28482 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 2/20 0.49
ALOX15 P16050 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
XBP1 P17861 1/20 0.47
NTSR1 P30989 1/20 0.46
GRIN1 Q05586 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147688 0.94 NR3C1 (1.00) NR3C1ALDH1A1NPSR1HTTMAPK1
SCHEMBL4143690 0.91 NR3C1 (0.88) NR3C1ALDH1A1NPSR1HTTMAPK1
SCHEMBL4142904 0.89 NR3C1 (0.84) NR3C1ALDH1A1NPSR1HTTMAPK1
SCHEMBL4142900 0.88 NR3C1 (0.82) NR3C1ALDH1A1NPSR1HTTMAPK1
SCHEMBL4143694 0.85 NR3C1 (1.00) NR3C1ALDH1A1NPSR1HTTMAPK1
SCHEMBL4143729 0.84 NR3C1 (1.00) NR3C1ALDH1A1NPSR1HTT
SCHEMBL4142829 0.83 NR3C1 (1.00) NR3C1ALDH1A1NPSR1HTTMAPK1
SCHEMBL4135159 0.82 NR3C1 (0.77) NR3C1ALDH1A1NPSR1HTTMAPK1
SCHEMBL4151366 0.81 NR3C1 (1.00) NR3C1
SCHEMBL4147641 0.80 NR3C1 (0.73) NR3C1ALDH1A1NPSR1HTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
US-7576076-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2009-08-18 US disclosed
US-7576076-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS NR3C1, NR3C2, TYMS NR3C1 1/4885ALDH1A1 3275/4885NPSR1 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.